Birgitta Stymne Göransson elected member of LEO Pharma’s Board of Directors

Birgitta Stymne Göransson has worked as non-executive Boardmember, Chairman and Committee Chair of several boards and audit committees and has more than 25 years of experience in medtech and IT/tech as well as consulting, consumer retail and branded goods.
Birgitta Stymne Göransson’s current chairmanships include BCB Medical Oy and Industrifonden in Sweden as well as Chair of the Audit Committees of Elekta AB and Pandora AS. In her previous executive roles, she has among other worked as Industrial Advisor to Ratos AB, and held positions as Chief Executive at Memira Holding AB and Semantix Group AB.
Olivier Bohuon, Chairman of the Board of Directors at LEO Pharma A/S, says: “We are pleased to welcome Birgitta Stymne Göransson to the Board of Directors. With her broad industry insights and deep financial experience from both public and private companies, she will play an important role in the realization of LEO Pharma’s ambitious growth strategy.”
Birgitta Stymne Göransson holds an MBA from Harvard Business School, MA, USA as well as a M.Sc. in Chemical Engineering and Biotechnology from the Royal Institute of Technology in Sweden.
Contacts
Trine Juul Wengel
Global External Communications, LEO Pharma A/S
Tel.: (+45) 20732037
Email: tewdk@leo-pharma.com
Images

About LEO Pharma
About LEO Pharma A/S
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit.
Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 76 million patients in 130 countries. In 2018, the company generated net sales of DKK 10,410 million.
For more information, visit www.leo-pharma.com or follow us on LinkedIn: www.linkedin.com/company/leo-pharma
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma Announces Positive Topline 32-Week Key Results in ADHAND Trial17.11.2025 09:00:00 CET | Pressemeddelelse
The ADHAND trial evaluates the efficacy and safety of tralokinumab in adult patients living with atopic dermatitis with moderate-to-severe hand involvement,1 a high burden, high unmet need population.2 At Week 16, tralokinumab showed statistically significant improvement compared to placebo in all primary and key secondary endpoints such as clear or almost clear skin, itch and pain.3 The 32-week results of the ADHAND trial builds on the positive findings observed at Week 16.
LEO Pharma delivers 8% revenue growth at CER in 9M 2025 and updates full-year outlook6.11.2025 09:00:00 CET | Pressemeddelelse
Ballerup, Denmark, 6 November, 2025 - In the first nine months of 2025, LEO Pharma continued its robust revenue growth, with significantly improved profitability and free cash flow. As expected, growth accelerated in the third quarter, with the global rollout of Anzupgo® gaining further momentum after its September launch in the U.S. The 2025 financial outlook is updated to reflect the addition of Spevigo® to the portfolio, reinforcing LEO Pharma’s commitment to advancing innovation and expanding access to care. Highlights LEO Pharma’s revenue increased by 7% to DKK 10,064 million, and by 8% at constant exchange rates (CER), entirely driven by organic growth. The revenue growth was led by North America (+27% at CER), with Europe (+2% at CER) and Rest of World (+6% at CER) also contributing to the overall growth. Revenue from the Dermatology portfolio grew by 9% (CER), driven by the Strategic brands Adtralza®/Adbry® and Anzupgo®, which combined had a revenue increase of 41% (CER), in ad
LEO Pharma announces NICE recommendation of reimbursement in England and Wales5.11.2025 12:00:00 CET | Pressemeddelelse
The National Institute for Health and Care Excellence (NICE) has recommended the first-and-only topical treatment for adults in the United Kingdom specifically approved for moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate.1 The Technology Appraisal Guidance (TAG) means NHS organisations in England and Wales must now make Anzupgo® ▼(delgocitinib) cream available for healthcare professionals to prescribe. CHE affects around 4.4 million2,3 adults in the UK, with 70% of those with severe forms reporting problems performing everyday activities4, and 58% saying it interferes with their ability to work5.
LEO Pharma strengthens leadership in medical dermatology with the appointment of Sophie Lamle as Chief Development Officer3.11.2025 12:00:00 CET | Pressemeddelelse
Sophie Lamle brings over 20 years of experience in the pharmaceutical industry, leading innovation, clinical development, and strategic transformation. Her appointment will further strengthen LEO Pharma’s Search & Develop innovation model, unlocking value with a focus on differentiated assets.
LEO Pharma continues global rollout of Anzupgo® (delgocitinib) cream with submission of New Drug Application in China16.10.2025 15:30:00 CEST | Pressemeddelelse
LEO Pharma is seeking to expand the availability of Anzupgo® (delgocitinib) cream to China, as the company announces the submission of a New Drug Application (NDA) to the National Medical Products Administration (NMPA), which has been accepted for review for adult patients with moderate to severe chronic hand eczema. The NDA is supported by results from DELTA China, a phase 3 trial with Anzupgo in Chinese adults with moderate to severe chronic hand eczema (CHE)1 along with the full clinical program of delgocitinib, which includes data from DELTA 1,2 and 3, DELTA Force and DELTA Teen.2-7 The Anzupgo NDA submission demonstrates LEO Pharma's commitment to providing additional treatment options for patients living with skin diseases in China.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
